Imatinib

Drug information

Full prescribing information, Novartis (PDF)

Indications

Chronic Myeloid Leukemia

Dose: 400-800 mg po qd

References

Druker BJ et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Eng J Med 2006; 355:2408

O’Brien SG et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Eng J Med 2003; 348:994.

Druker BJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myelogenous leukemia. N Engl J Med 2001; 344:1031

Druker BJ et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia or acute lymphoblastic leukemia with the Philadelphia chromosome. N Eng J Med 2001; 344:1038.

Myelodysplastic syndrome

for MDS/MPD associated with PDGFR gene re-arrangement

400 mg po qd

FDA approval on 10/19/06

References

David M et al. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood 2007; 109:61